989 results on '"Reiter, Robert E."'
Search Results
52. INTERNATIONAL VARIATIONS IN QUALITY METRICS FOR LOCALIZED PROSTATE CANCER
- Author
-
Weiner, Adam B., primary, Nguyen, Anissa V., additional, Reiter, Robert E., additional, and Litwin, Mark S., additional
- Published
- 2024
- Full Text
- View/download PDF
53. Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)
- Author
-
Ma, Ting Martin, Chu, Fang-I, Sandler, Howard, Feng, Felix Y., Efstathiou, Jason A., Jones, Christopher U., Roach, Mack, 3rd, Rosenthal, Seth A., Pisansky, Thomas, Michalski, Jeff M., Bolla, Michel, de Reijke, Theo M., Maingon, Philippe, Neven, Anouk, Denham, James, Steigler, Allison, Joseph, David, Nabid, Abdenour, Souhami, Luis, Carrier, Nathalie, Incrocci, Luca, Heemsbergen, Wilma, Pos, Floris J., Sydes, Matthew R., Dearnaley, David P., Tree, Alison C., Syndikus, Isabel, Hall, Emma, Cruickshank, Clare, Malone, Shawn, Roy, Soumyajit, Sun, Yilun, Zaorsky, Nicholas G., Nickols, Nicholas G., Reiter, Robert E., Rettig, Matthew B., Steinberg, Michael L., Reddy, Vishruth K., Xiang, Michael, Romero, Tahmineh, Spratt, Daniel E., and Kishan, Amar U.
- Published
- 2022
- Full Text
- View/download PDF
54. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study
- Author
-
Lenis, Andrew T., Pooli, Aydin, Lec, Patrick M., Sadun, Taylor Y., Johnson, David C., Lebacle, Cedric, Fendler, Wolfgang P., Eiber, Matthias, Czernin, Johannes, Reiter, Robert E., and Calais, Jeremie
- Published
- 2022
- Full Text
- View/download PDF
55. Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer
- Author
-
Houlahan, Kathleen E, Salmasi, Amirali, Sadun, Taylor Y, Pooli, Aydin, Felker, Ely R, Livingstone, Julie, Huang, Vincent, Raman, Steven S, Ahuja, Preeti, Sisk, Anthony E, Boutros, Paul C, and Reiter, Robert E
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Prostate Cancer ,Aging ,Urologic Diseases ,Cancer ,Biomedical Imaging ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,Aged ,Gene Dosage ,Gene Expression Profiling ,Genome ,Humans ,Male ,Middle Aged ,Multiparametric Magnetic Resonance Imaging ,Prostatic Neoplasms ,RNA ,Long Noncoding ,RNA ,Messenger ,RNA ,Small Nuclear ,Transcriptome ,Tumor Burden ,Tumor Microenvironment ,Prostate cancer ,Multiparametric magnetic resonance imaging visibility ,Radiogenomics ,Nimbosus ,Transcriptomics ,Urology & Nephrology ,Clinical sciences - Abstract
Multiparametric magnetic resonance imaging (mpMRI) has transformed the management of localized prostate cancer by improving identification of clinically significant disease at diagnosis. Approximately 20% of primary prostate tumors are invisible to mpMRI, and we hypothesize that this invisibility reflects fundamental molecular properties of the tumor. We therefore profiled the genomes and transcriptomes of 40 International Society of Urological Pathology grade 2 tumors: 20 mpMRI-invisible (Prostate Imaging-Reporting and Data System [PI-RADS] v2
- Published
- 2019
56. Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models
- Author
-
Zhang, Mo, Kobayashi, Naoko, Zettlitz, Kirstin A, Kono, Evelyn A, Yamashiro, Joyce M, Tsai, Wen-Ting K, Jiang, Ziyue K, Tran, Chau P, Wang, Chung, Guan, Johnny, Wu, Anna M, and Reiter, Robert E
- Subjects
Biotechnology ,Cancer ,Animals ,Antigens ,Surface ,Cell Line ,Tumor ,Disease Models ,Animal ,Fluorescence ,Gene Expression Regulation ,Neoplastic ,Glutamate Carboxypeptidase II ,Heterografts ,Humans ,Indoles ,Infrared Rays ,Male ,Margins of Excision ,Mice ,Optical Imaging ,Prostate ,Prostatectomy ,Prostatic Neoplasms ,Spectroscopy ,Near-Infrared ,Surgery ,Computer-Assisted ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeThe inability to intraoperatively distinguish primary tumor, as well as lymphatic spread, increases the probability of positive surgical margins, tumor recurrence, and surgical toxicity. The goal of this study was to develop a tumor-specific optical probe for real-time fluorescence-guided surgery.Experimental designA humanized antibody fragment against PSCA (A11 minibody, A11 Mb) was conjugated with a near-infrared fluorophore, IRDye800CW. The integrity and binding of the probe to PSCA were confirmed by gel electrophoresis, size-exclusion chromatography, and flow cytometry, respectively. The ability of the probe to detect tumor-infiltrated lymph nodes and metastatic lesions was evaluated in 2 xenograft models, as well as in transgenic mice expressing human PSCA (hPSCA). An invasive intramuscular model was utilized to evaluate the efficacy of the A11 Mb-IRDye800CW-guided surgery.ResultsA11 Mb was successfully conjugated with IRDye800CW and retained specific binding to PSCA. In vivo imaging showed maximal signal-to-background ratios at 48 hours. The A11 Mb-IRDye800CW specifically detected PSCA-positive primary tumors, tumor-infiltrated lymph nodes, and distant metastases with high contrast. Fluorescence guidance facilitated more complete tumor resection, reduced tumor recurrence, and improved overall survival, compared with conventional white light surgery. The probe successfully identified primary orthotopic tumors and metastatic lesions in hPSCA transgenic mice.ConclusionsReal-time fluorescence image-guided surgery with A11 Mb-IRDye800CW enabled detection of lymph node metastases and positive surgical margins, facilitated more complete tumor removal, and improved survival, compared with white light surgery. These results may be translatable into clinical practice to improve surgical and patient outcomes.
- Published
- 2019
57. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
- Author
-
Lückerath, Katharina, Wei, Liu, Fendler, Wolfgang P, Evans-Axelsson, Susan, Stuparu, Andreea D, Slavik, Roger, Mona, Christine E, Calais, Jeremie, Rettig, Matthew, Reiter, Robert E, Herrmann, Ken, Radu, Caius G, Czernin, Johannes, and Eiber, Matthias
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Aging ,Urologic Diseases ,Clinical Trials and Supportive Activities ,Biomedical Imaging ,Prostate Cancer ,Radiation Oncology ,Cancer ,5.1 Pharmaceuticals ,PSMA ,Prostate cancer ,Ga-68-PSMA PET ,CT ,Androgen receptor blockade ,Radioligand therapy ,68Ga-PSMA PET/CT ,Medical Biochemistry and Metabolomics ,Clinical sciences ,Oncology and carcinogenesis - Abstract
BackgroundProstate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a promising yet not curative approach in castration-resistant (CR) prostate cancer (PC). Rational combination therapies may improve treatment efficacy. Here, we explored the effect of androgen receptor blockade (ARB) on PSMA expression visualized by PET and its potential additive effect when combined with 177Lu-PSMA RLT in a mouse model of prostate cancer.MethodsMice bearing human CRPC (C4-2 cells) xenografts were treated with 10 mg/kg enzalutamide (ENZ), with 50 mg/kg bicalutamide (BIC), or vehicle (control) for 21 days. PSMA expression was evaluated by 68Ga-PSMA11 PET/CT and quantified by flow cytometry of tumor fine needle aspirations before treatment and on days 23, 29, 34, and 39 post-therapy induction. For the RLT combination approach, mice bearing C4-2 tumors were treated with 10 mg/kg ENZ or vehicle for 21 days before receiving either 15 MBq (84 GBq/μmol) 177Lu-PSMA617 or vehicle. DNA damage was assessed as phospho-γH2A.X foci in tumor biopsies. Reduction of tumor volume on CT and survival were used as study endpoints.ResultsTumor growth was delayed by ARB while 68Ga-PSMA11 uptake increased up to 2.3-fold over time when compared to controls. ABR-induced upregulation of PSMA expression was confirmed by flow cytometry. Phospho-γH2A.X levels increased 1.8- and 3.4-fold at 48 h in response to single treatment ENZ or RLT and ENZ+RLT, respectively. Despite significantly greater DNA damage and persistent increase of PSMA expression at the time of RLT, no additional tumor growth retardation was observed in the ENZ+RLT group (vs. RLT only, p = 0.372 at day 81). Median survival did not improve significantly when ENZ was combined with RLT.ConclusionARB-mediated increases in PSMA expression in PC xenografts were evident by 68Ga-PSMA11 PET imaging and flow cytometry. 177Lu-PSMA617 effectively decreased C4-2 tumor size. However, while pre-treatment with ARB increased DNA damage significantly, it did not result in synergistic effects when combined with RLT.
- Published
- 2018
58. 3T multiparametric MR imaging, PIRADSv2-based detection of index prostate cancer lesions in the transition zone and the peripheral zone using whole mount histopathology as reference standard
- Author
-
Asvadi, Nazanin Hajarol, Afshari Mirak, Sohrab, Mohammadian Bajgiran, Amirhossein, Khoshnoodi, Pooria, Wibulpolprasert, Pornphan, Margolis, Daniel, Sisk, Anthony, Reiter, Robert E, and Raman, Steven S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Aging ,Prostate Cancer ,Urologic Diseases ,Biomedical Imaging ,Clinical Research ,Cancer ,Aged ,Humans ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Neoplasm Grading ,Neoplasm Staging ,Prostate-Specific Antigen ,Prostatectomy ,Prostatic Neoplasms ,Retrospective Studies ,Tumor Burden ,Prostate cancer ,Multiparametric magnetic resonance imaging ,PI-RADSv2 ,Gleason score - Abstract
PurposeTo evaluate 3T mpMRI characteristics of transition zone and peripheral zone index prostate cancer lesions stratified by Gleason Score and PI-RADSv2 with whole mount histopathology correlation.MethodsAn institution review board-approved, HIPAA-compliant single-arm observational study of 425 consecutive men with 3T mpMRI prior to radical prostatectomy from December 2009 to October 2016 was performed. A genitourinary radiologist and a genitourinary pathologist matched all lesions detected on whole mount histopathology with lesions concordant for size and location on 3T mpMRI. Differences in clinical, MRI parameters, and histopathology between transition zone and peripheral zone were determined and analyzed with χ2 and Mann-Whitney U test. AUC was measured.Results3T mpMRI detected 248/323 (76.7%) index lesions in peripheral zone and 75/323 (23.2%) in transition zone. Transition zone prostate cancer had higher median prostate-specific antigen (p = 0.001), larger tumor on 3T mpMRI (p = 0.001), lower proportions of PI-RADSv2 category 4 and 5 (p
- Published
- 2018
59. Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer
- Author
-
Calais, Jeremie, Kishan, Amar U, Cao, Minsong, Fendler, Wolfgang P, Eiber, Matthias, Herrmann, Ken, Ceci, Francesco, Reiter, Robert E, Rettig, Matthew B, Hegde, John V, Shaverdian, Narek, King, Chris R, Steinberg, Michael L, Czernin, Johannes, and Nickols, Nicholas G
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Radiation Oncology ,Clinical Research ,Clinical Trials and Supportive Activities ,Aging ,Cancer ,Prostate Cancer ,Bioengineering ,Biomedical Imaging ,Urologic Diseases ,Aged ,Aged ,80 and over ,Cohort Studies ,Computer Simulation ,Edetic Acid ,Gallium Isotopes ,Gallium Radioisotopes ,Humans ,Lymphatic Metastasis ,Male ,Middle Aged ,Neoplasm Staging ,Oligopeptides ,Positron Emission Tomography Computed Tomography ,Prospective Studies ,Prostate ,Prostatic Neoplasms ,Radiopharmaceuticals ,Radiotherapy Planning ,Computer-Assisted ,Seminal Vesicles ,prostate cancer ,PSMA ,PET/CT ,initial staging ,definitive radiotherapy ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
Standard-of-care imaging for initial staging of prostate cancer (PCa) underestimates disease burden. Prostate-specific membrane antigen (PSMA) PET/CT detects PCa metastasis with superior accuracy, having a potential impact on the planning of definitive radiation therapy (RT) for nonmetastatic PCa. Our objectives were to determine how often definitive RT planning based on standard target volumes covers 68Ga-PSMA-11 PET/CT-defined disease and to assess the potential impact of 68Ga-PSMA-11 PET/CT on definitive RT planning. Methods: This was a post hoc analysis of an intention-to-treat population of 73 patients with localized PCa without prior local therapy who underwent 68Ga-PSMA PET/CT for initial staging as part of an investigational new drug trial. Eleven of the 73 were intermediate-risk (15%), 33 were high-risk (45%), 22 were very-high-risk (30%), and 7 were N1 (9.5%). Clinical target volumes (CTVs), which included the prostate, seminal vesicles, and (in accord with the Radiation Therapy Oncology Group consensus guidelines) pelvic lymph nodes (LNs), were contoured on the CT portion of the PET/CT images by a radiation oncologist masked to the PET findings. 68Ga-PSMA-11 PET/CT images were analyzed by a nuclear medicine physician. 68Ga-PSMA-11-positive lesions not covered by planning volumes based on the CTVs were considered to have a major potential impact on treatment planning. Results: All patients had one or more 68Ga-PSMA-11-positive primary prostate lesions. Twenty-five (34%) and 7 (9.5%) of the 73 patients had 68Ga-PSMA-11-positive pelvic LN and distant metastases, respectively. The sites of LN metastases in decreasing order of frequency were external iliac (20.5%), common iliac (13.5%), internal iliac (12.5%) obturator (12.5%), perirectal (4%), abdominal (4%), upper diaphragm (4%), and presacral (1.5%). The median size of the LN lesions was 6 mm (range, 4-24 mm). RT planning based on the CTVs covered 69 (94.5%) of the 73 primary lesions and 20 (80%) of the 25 pelvic LN lesions, on a per-patient analysis. Conclusion:68Ga-PSMA-11 PET/CT had a major impact on intended definitive RT planning for PCa in 12 (16.5%) of the 73 patients whose RT fields covered the prostate, seminal vesicles, and pelvic LNs and in 25 (37%) of the 66 patients whose RT fields covered the prostate and seminal vesicles but not the pelvic LNs.
- Published
- 2018
60. Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate
- Author
-
Nagarajan, Mahesh B, Raman, Steven S, Lo, Pechin, Lin, Wei-Chan, Khoshnoodi, Pooria, Sayre, James W, Ramakrishna, Bharath, Ahuja, Preeti, Huang, Jiaoti, Margolis, Daniel JA, Lu, David SK, Reiter, Robert E, Goldin, Jonathan G, Brown, Matthew S, and Enzmann, Dieter R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Aging ,Prostate Cancer ,Urologic Diseases ,Biomedical Imaging ,Clinical Research ,Cancer ,Adult ,Aged ,Algorithms ,Biopsy ,Humans ,Image Interpretation ,Computer-Assisted ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Neoplasm Grading ,Probability ,Prostatectomy ,Prostatic Neoplasms ,Retrospective Studies ,Prostate cancer ,Multi-parametric ,MRI ,Tumor occurrence probability map ,Prostate registration ,Multi-parametric MRI - Abstract
PurposeWe present a method for generating a T2 MR-based probabilistic model of tumor occurrence in the prostate to guide the selection of anatomical sites for targeted biopsies and serve as a diagnostic tool to aid radiological evaluation of prostate cancer.Materials and methodsIn our study, the prostate and any radiological findings within were segmented retrospectively on 3D T2-weighted MR images of 266 subjects who underwent radical prostatectomy. Subsequent histopathological analysis determined both the ground truth and the Gleason grade of the tumors. A randomly chosen subset of 19 subjects was used to generate a multi-subject-derived prostate template. Subsequently, a cascading registration algorithm involving both affine and non-rigid B-spline transforms was used to register the prostate of every subject to the template. Corresponding transformation of radiological findings yielded a population-based probabilistic model of tumor occurrence. The quality of our probabilistic model building approach was statistically evaluated by measuring the proportion of correct placements of tumors in the prostate template, i.e., the number of tumors that maintained their anatomical location within the prostate after their transformation into the prostate template space.ResultsProbabilistic model built with tumors deemed clinically significant demonstrated a heterogeneous distribution of tumors, with higher likelihood of tumor occurrence at the mid-gland anterior transition zone and the base-to-mid-gland posterior peripheral zones. Of 250 MR lesions analyzed, 248 maintained their original anatomical location with respect to the prostate zones after transformation to the prostate.ConclusionWe present a robust method for generating a probabilistic model of tumor occurrence in the prostate that could aid clinical decision making, such as selection of anatomical sites for MR-guided prostate biopsies.
- Published
- 2018
61. Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer
- Author
-
Lückerath, Katharina, Stuparu, Andreea D, Wei, Liu, Kim, Woosuk, Radu, Caius G, Mona, Christine E, Calais, Jeremie, Rettig, Matthew, Reiter, Robert E, Czernin, Johannes, Slavik, Roger, Herrmann, Ken, Eiber, Matthias, and Fendler, Wolfgang P
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Urologic Diseases ,Biomedical Imaging ,Bioengineering ,Prostate Cancer ,Good Health and Well Being ,Animals ,Biological Transport ,Cell Line ,Tumor ,Disease Models ,Animal ,Edetic Acid ,Gallium Isotopes ,Gallium Radioisotopes ,Gene Expression Regulation ,Neoplastic ,Image Processing ,Computer-Assisted ,Male ,Mice ,Mice ,Inbred C57BL ,Oligopeptides ,Positron Emission Tomography Computed Tomography ,Prostatic Neoplasms ,Reproducibility of Results ,PSMA ,prostate cancer ,PET ,threshold ,reproducibility ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
To improve prostate-specific membrane antigen (PSMA)-targeted theranostic approaches, robust murine models of prostate cancer are needed. However, important characteristics of preclinical PSMA imaging-that is, the reproducibility of the imaging signal and the relationship between quantitative cell surface PSMA expression and lesion detectability with small-animal PET/CT-have not been defined yet. Methods: Murine prostate cancer RM1 sublines (ras myc transformed cells of C57BL/6 prostate origin) expressing varying levels of human PSMA were injected into the shoulder of C57BL/6 mice on day 0. 68Ga-PSMA11 PET/CT was performed on days 7 and 8 and interpreted by 2 masked readers to determine interday and interreader reproducibility. PSMA expression was quantified on days 7 and 8 by flow cytometry of fine-needle aspiration tumor biopsy samples. Cell surface PSMA expression was correlated with PET signal. The threshold for PET positivity was based on the clinical Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria. Results: The maximum and average percentages of injected 68Ga-PSMA11 activity per gram of tissue (%IA/g) correlated nearly perfectly as determined by 2 independent readers and on 2 separate days (intraclass correlation coefficient, 1.00/0.89 and 0.95/0.88, respectively). The number of PSMA molecules per cell increased from the RM1-yellow fluorescent protein subline (PSMA-; 2,000/cell) to the RM1-low subline (PSMA+; 17,000/cell), the RM1-medium subline (PSMA++; 22,000/cell), and the RM1-PGLS subline (PSMA-positive, green fluorescent protein-positive, and luciferase-positive; PSMA+++; 45,000/cell). Expression levels correlated with the visual positivity rate on 68Ga-PSMA11 PET and with the PSMA PET %IA/g. The PSMA threshold for PET positivity was approximately 20,000 per cell. Signal correlation was close at lower PSMA levels (RM1-low to RM1-medium; 10-23 %IA/g) but was lost at higher PSMA levels (RM1-medium to RM1-PGLS; 23-27 %IA/g). Conclusion: The in vivo relationship between 68Ga-PSMA11 PET/CT and PSMA expression level in a murine model of prostate cancer was robust for lower cell surface PSMA expression levels (≤22,000/cell). Thus, preclinical 68Ga-PSMA11 PET/CT can be used as an imaging biomarker to test PSMA-targeted interventions in murine models.
- Published
- 2018
62. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium
- Author
-
Kishan, Amar U., Wang, Xiaoyan, Sun, Yilun, Romero, Tahmineh, Michalski, Jeff M., Ma, Ting Martin, Feng, Felix Y., Sandler, Howard M., Bolla, Michel, Maingon, Philippe, De Reijke, Theo, Neven, Anouk, Steigler, Allison, Denham, James W., Joseph, David, Nabid, Abdenour, Carrier, Nathalie, Souhami, Luis, Sydes, Matt R., Dearnaley, David P., Syndikus, Isabel, Tree, Alison C., Incrocci, Luca, Heemsbergen, Wilma D., Pos, Floris J., Zapatero, Almudena, Efstathiou, Jason A., Guerrero, Araceli, Alvarez, Ana, San-Segundo, Carmen Gonzalez, Maldonado, Xavier, Xiang, Michael, Rettig, Matthew B., Reiter, Robert E., Zaorsky, Nicholas G., Ong, Wee Loon, Dess, Robert T., Steinberg, Michael L., Nickols, Nicholas G., Roy, Soumyajit, Garcia, Jorge A., and Spratt, Daniel E.
- Published
- 2022
- Full Text
- View/download PDF
63. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis
- Author
-
Kishan, Amar U, Sun, Yilun, Hartman, Holly, Pisansky, Thomas M, Bolla, Michel, Neven, Anouk, Steigler, Allison, Denham, James W, Feng, Felix Y, Zapatero, Almudena, Armstrong, John G, Nabid, Abdenour, Carrier, Nathalie, Souhami, Luis, Dunne, Mary T, Efstathiou, Jason A, Sandler, Howard M, Guerrero, Araceli, Joseph, David, Maingon, Philippe, de Reijke, Theo M, Maldonado, Xavier, Ma, Ting Martin, Romero, Tahmineh, Wang, Xiaoyan, Rettig, Matthew B, Reiter, Robert E, Zaorsky, Nicholas G, Steinberg, Michael L, Nickols, Nicholas G, Jia, Angela Y, Garcia, Jorge A, and Spratt, Daniel E
- Published
- 2022
- Full Text
- View/download PDF
64. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
- Author
-
Quigley, David A, Dang, Ha X, Zhao, Shuang G, Lloyd, Paul, Aggarwal, Rahul, Alumkal, Joshi J, Foye, Adam, Kothari, Vishal, Perry, Marc D, Bailey, Adina M, Playdle, Denise, Barnard, Travis J, Zhang, Li, Zhang, Jin, Youngren, Jack F, Cieslik, Marcin P, Parolia, Abhijit, Beer, Tomasz M, Thomas, George, Chi, Kim N, Gleave, Martin, Lack, Nathan A, Zoubeidi, Amina, Reiter, Robert E, Rettig, Matthew B, Witte, Owen, Ryan, Charles J, Fong, Lawrence, Kim, Won, Friedlander, Terence, Chou, Jonathan, Li, Haolong, Das, Rajdeep, Li, Hui, Moussavi-Baygi, Ruhollah, Goodarzi, Hani, Gilbert, Luke A, Lara, Primo N, Evans, Christopher P, Goldstein, Theodore C, Stuart, Joshua M, Tomlins, Scott A, Spratt, Daniel E, Cheetham, R Keira, Cheng, Donavan T, Farh, Kyle, Gehring, Julian S, Hakenberg, Jörg, Liao, Arnold, Febbo, Philip G, Shon, John, Sickler, Brad, Batzoglou, Serafim, Knudsen, Karen E, He, Housheng H, Huang, Jiaoti, Wyatt, Alexander W, Dehm, Scott M, Ashworth, Alan, Chinnaiyan, Arul M, Maher, Christopher A, Small, Eric J, and Feng, Felix Y
- Subjects
Humans ,Prostatic Neoplasms ,Neoplasm Metastasis ,Cyclin-Dependent Kinases ,Proto-Oncogene Proteins c-myc ,BRCA2 Protein ,Receptors ,Androgen ,Gene Expression Profiling ,Genomics ,Tandem Repeat Sequences ,Mutation ,Aged ,Aged ,80 and over ,Middle Aged ,Male ,Tumor Suppressor Protein p53 ,Genomic Structural Variation ,DNA Copy Number Variations ,Exome ,Whole Genome Sequencing ,BRCA2 ,androgen receptor ,castration resistant prostate cancer ,chromothripsis ,gene fusion ,genomics ,metastases ,structural variation ,tandem duplication ,whole-genome sequencing ,Biological Sciences ,Medical and Health Sciences ,Developmental Biology - Abstract
While mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. Through integrative deep whole-genome and -transcriptome analysis of 101 castration-resistant prostate cancer metastases (109X tumor/38X normal coverage), we identified structural variants altering critical regulators of tumorigenesis and progression not detectable by exome approaches. Notably, we observed amplification of an intergenic enhancer region 624 kb upstream of the androgen receptor (AR) in 81% of patients, correlating with increased AR expression. Tandem duplication hotspots also occur near MYC, in lncRNAs associated with post-translational MYC regulation. Classes of structural variations were linked to distinct DNA repair deficiencies, suggesting their etiology, including associations of CDK12 mutation with tandem duplications, TP53 inactivation with inverted rearrangements and chromothripsis, and BRCA2 inactivation with deletions. Together, these observations provide a comprehensive view of how structural variations affect critical regulators in metastatic prostate cancer.
- Published
- 2018
65. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology
- Author
-
Tan, Nelly, Shen, Luyao, Khoshnoodi, Pooria, Alcalá, Héctor E, Yu, Weixia, Hsu, William, Reiter, Robert E, Lu, David Y, and Raman, Steven S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Clinical Research ,Aging ,Biomedical Imaging ,Urologic Diseases ,Prostate Cancer ,Aged ,Biopsy ,False Positive Reactions ,Humans ,Magnetic Resonance Imaging ,Male ,Margins of Excision ,Middle Aged ,Neoplasm Grading ,Neoplasm Recurrence ,Local ,Neoplasm Staging ,Preoperative Care ,Prognosis ,Prostate ,Prostate-Specific Antigen ,Prostatectomy ,Prostatic Neoplasms ,Robotic Surgical Procedures ,Survival Analysis ,Treatment Outcome ,Tumor Burden ,prostatic neoplasms ,neoplasm recurrence ,local ,prostate specific antigen ,magnetic resonance imaging ,biomarkers ,tumor ,Urology & Nephrology ,Clinical sciences - Abstract
PurposeWe sought to identify the clinical and magnetic resonance imaging variables predictive of biochemical recurrence after robotic assisted radical prostatectomy in patients who underwent multiparametric 3 Tesla prostate magnetic resonance imaging.Materials and methodsWe performed an institutional review board approved, HIPAA (Health Insurance Portability and Accountability Act) compliant, single arm observational study of 3 Tesla multiparametric magnetic resonance imaging prior to robotic assisted radical prostatectomy from December 2009 to March 2016. Clinical, magnetic resonance imaging and pathological information, and clinical outcomes were compiled. Biochemical recurrence was defined as prostate specific antigen 0.2 ng/cc or greater. Univariate and multivariate regression analysis was performed.ResultsBiochemical recurrence had developed in 62 of the 255 men (24.3%) included in the study at a median followup of 23.5 months. Compared to the subcohort without biochemical recurrence the subcohort with biochemical recurrence had a greater proportion of patients with a high grade biopsy Gleason score, higher preoperative prostate specific antigen (7.4 vs 5.6 ng/ml), intermediate and high D'Amico classifications, larger tumor volume on magnetic resonance imaging (0.66 vs 0.30 ml), higher PI-RADS® (Prostate Imaging-Reporting and Data System) version 2 category lesions, a greater proportion of intermediate and high grade radical prostatectomy Gleason score lesions, higher pathological T3 stage (all p
- Published
- 2018
66. Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence
- Author
-
Calais, Jeremie, Fendler, Wolfgang P, Eiber, Matthias, Gartmann, Jeannine, Chu, Fang-I, Nickols, Nicholas G, Reiter, Robert E, Rettig, Matthew B, Marks, Leonard S, Ahlering, Thomas E, Huynh, Linda M, Slavik, Roger, Gupta, Pawan, Quon, Andrew, Allen-Auerbach, Martin S, Czernin, Johannes, and Herrmann, Ken
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Urologic Diseases ,Aging ,Prostate Cancer ,Biomedical Imaging ,Aged ,Edetic Acid ,Gallium Isotopes ,Gallium Radioisotopes ,Humans ,Male ,Oligopeptides ,Positron Emission Tomography Computed Tomography ,Prostatic Neoplasms ,Recurrence ,prostate cancer ,biochemical recurrence ,PET/CT ,Ga-68-PSMA ,impact on implemented management ,68Ga-PSMA ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
In this prospective survey of referring physicians, we investigated whether and how 68Ga-labeled prostate-specific membrane antigen 11 (68Ga-PSMA-11) PET/CT affects the implemented management of prostate cancer patients with biochemical recurrence (BCR). Methods: We conducted a prospective survey of physicians (NCT02940262) who referred 161 patients with prostate cancer BCR (median prostate-specific antigen value, 1.7 ng/mL; range, 0.05-202 ng/mL). Referring physicians completed one questionnaire before the scan to indicate the treatment plan without 68Ga-PSMA-11 PET/CT information (Q1; n = 101), one immediately after the scan to denote intended management changes (Q2; n = 101), and one 3-6 mo later to document the final implemented management (Q3; n = 56). The implemented management was also obtained via electronic chart review or patient contact (n = 45). Results: A complete documented management strategy (Q1 + Q2 + implemented management) was available for 101 of 161 patients (63%). Seventy-six of these (75%) had a positive 68Ga-PSMA-11 PET/CT result. The implemented management differed from the prescan intended management (Q1) in 54 of 101 patients (53%). The postscan intended management (Q2) differed from the prescan intended management (Q1) in 62 of 101 patients (61%); however, these intended changes were not implemented in 29 of 62 patients (47%). Pelvic nodal and extrapelvic metastatic disease on 68Ga-PSMA-11 PET/CT (PSMA T0N1M0 and PSMA T0N1M1 patterns) was significantly associated with implemented management changes (P = 0.001 and 0.05). Conclusion: Information from 68Ga-PSMA-11 PET/CT brings about management changes in more than 50% of prostate cancer patients with BCR (54/101; 53%). However, intended management changes early after 68Ga-PSMA-11 PET/CT frequently differ from implemented management changes.
- Published
- 2018
67. Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy
- Author
-
Nassiri, Nima, Chang, Edward, Lieu, Patricia, Priester, Alan M, Margolis, Daniel JA, Huang, Jiaoti, Reiter, Robert E, Dorey, Frederick J, Marks, Leonard S, and Natarajan, Shyam
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Urologic Diseases ,Prostate Cancer ,Biomedical Imaging ,Cancer ,Humans ,Image-Guided Biopsy ,Magnetic Resonance Imaging ,Male ,Multimodal Imaging ,Neoplasm Grading ,Patient Selection ,Prostate ,Prostatectomy ,Prostatic Neoplasms ,Retrospective Studies ,Sensitivity and Specificity ,Ultrasonography ,Interventional ,prostatic neoplasms ,biopsy ,magnetic resonance imaging ,ultrasonography ,risk factors - Abstract
PurposeWe assessed focal therapy eligibility in men who underwent multiparametric magnetic resonance imaging and targeted biopsy with correlation to whole mount histology after radical prostatectomy.Materials and methodsSubjects were selected from among the 454 men in whom targeted biopsy proven prostate cancer was derived from regions of interest on multiparametric magnetic resonance imaging from 2010 to 2016. Focal therapy eligibility was limited to a maximum Gleason score of 4 + 3 in regions of interest with or without other foci of low risk prostate cancer (Gleason score 3 + 3 and less than 4 mm). Men who did not meet NCCN® intermediate risk criteria were classified as ineligible for focal therapy. Of the 454 men 64 underwent radical prostatectomy and biopsy findings were compared to final pathology findings.ResultsOf the 454 men with a biopsy proven region of interest 175 (38.5%) were eligible for focal therapy. Fusion biopsy, which combined targeted and template biopsy, had 80.0% sensitivity (12 of 15 cases), 73.5% specificity (36 of 49) and 75.0% accuracy (48 of 64) for focal therapy eligibility. Targeted cores alone yielded 73.3% sensitivity (11 of 15 cases), 47.9% specificity (23 of 48) and 54.7% accuracy (35 of 64). Gleason score and extension across the midline differed in 4 and 9, respectively, of the 13 cases that showed discordant biopsy and whole mount histology.ConclusionsUsing intermediate risk eligibility criteria more than a third of men with a targeted biopsy proven lesion identified on multiparametric magnetic resonance imaging would have been eligible for focal therapy. Eligibility determined by fusion biopsy was concordant with whole mount histology in 75% of cases. Improved selection criteria are needed to reliably determine focal therapy eligibility.
- Published
- 2018
68. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
- Author
-
Wyatt, Alexander W, Annala, Matti, Aggarwal, Rahul, Beja, Kevin, Feng, Felix, Youngren, Jack, Foye, Adam, Lloyd, Paul, Nykter, Matti, Beer, Tomasz M, Alumkal, Joshi J, Thomas, George V, Reiter, Robert E, Rettig, Matthew B, Evans, Christopher P, Gao, Allen C, Chi, Kim N, Small, Eric J, and Gleave, Martin E
- Subjects
Genetics ,Cancer ,Human Genome ,Urologic Diseases ,Prostate Cancer ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,Good Health and Well Being ,Adenomatous Polyposis Coli Protein ,BRCA2 Protein ,Biomarkers ,Tumor ,Circulating Tumor DNA ,Class Ia Phosphatidylinositol 3-Kinase ,Cyclin-Dependent Kinase Inhibitor p27 ,DNA Copy Number Variations ,Humans ,Liquid Biopsy ,Male ,Mutation ,Neoplasm Metastasis ,Nuclear Proteins ,PTEN Phosphohydrolase ,Phosphatidylinositol 3-Kinases ,Prostatic Neoplasms ,Castration-Resistant ,Receptors ,Androgen ,Repressor Proteins ,Retinoblastoma Binding Proteins ,Tumor Suppressor Protein p53 ,Ubiquitin-Protein Ligases ,Wnt Signaling Pathway ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Real-time knowledge of the somatic genome can influence management of patients with metastatic castration-resistant prostate cancer (mCRPC). While routine metastatic tissue biopsy is challenging in mCRPC, plasma circulating tumor DNA (ctDNA) has emerged as a minimally invasive tool to sample the tumor genome. However, no systematic comparisons of matched "liquid" and "solid" biopsies have been performed that would enable ctDNA profiling to replace the need for direct tissue sampling. We performed targeted sequencing across 72 clinically relevant genes in 45 plasma cell-free DNA (cfDNA) samples collected at time of metastatic tissue biopsy. We compared ctDNA alterations with exome sequencing data generated from matched tissue and quantified the concordance of mutations and copy number alterations using the Fisher exact test and Pearson correlations. Seventy-five point six percent of cfDNA samples had a ctDNA proportion greater than 2% of total cfDNA. In these patients, all somatic mutations identified in matched metastatic tissue biopsies were concurrently present in ctDNA. Furthermore, the hierarchy of variant allele fractions for shared mutations was remarkably similar between ctDNA and tissue. Copy number profiles between matched liquid and solid biopsy were highly correlated, and individual copy number calls in clinically actionable genes were 88.9% concordant. Detected alterations included AR amplifications in 22 (64.7%) samples, SPOP mutations in three (8.8%) samples, and inactivating alterations in tumor suppressors TP53 , PTEN , RB1 , APC , CDKN1B , BRCA2 , and PIK3R1 . In several patients, ctDNA sequencing revealed robust changes not present in paired solid biopsy, including clinically relevant alterations in the AR, WNT, and PI3K pathways. Our study shows that, in the majority of patients, a ctDNA assay is sufficient to identify all driver DNA alterations present in matched metastatic tissue and supports development of DNA biomarkers to guide mCRPC patient management based on ctDNA alone.
- Published
- 2017
69. Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer
- Author
-
Hegde, John V, Veruttipong, Darlene, Said, Jonathan W, Reiter, Robert E, Steinberg, Michael L, King, Christopher R, and Kishan, Amar U
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Prevention ,Prostate Cancer ,Cancer ,Clinical Research ,Aging ,Urologic Diseases ,Aged ,Antigens ,Neoplasm ,Biomarkers ,Tumor ,Biopsy ,Combined Modality Therapy ,Disease-Free Survival ,Follow-Up Studies ,Humans ,Incidence ,Los Angeles ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Neoplasm Grading ,Neoplasm Recurrence ,Local ,Predictive Value of Tests ,Prostatectomy ,Prostatic Neoplasms ,RNA ,Neoplasm ,ROC Curve ,Retrospective Studies ,Risk Factors ,Seminal Vesicles ,Survival Rate ,Tomography ,X-Ray Computed ,Urology & Nephrology ,Clinical sciences - Abstract
ObjectiveTo evaluate whether preoperative urinary prostate cancer antigen 3 (PCA3) scores predict for adverse pathologic features (APFs) or progression-free survival (PFS) in men with intermediate- or high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).Materials and methodsOne hundred nine men with intermediate- (n = 52) or high-risk (n = 57) PCa who underwent RP were retrospectively identified. Logistic regression analysis was performed to evaluate the association of PCA3 score with various APFs (eg, extracapsular extension, seminal vesicle invasion, etc.). Among 78 men with ≥1 year of follow-up, the association between PCA3 score and PFS was assessed using Cox regression analysis.ResultsAt RP, 52% of patients had at least 1 APF, and with median follow-up of 2.3 years, overall 3-year PFS was 70%. PCA3 was not a significant predictor of any APF on multivariate analysis (MVA), whereas canonical predictors (eg, biopsy Gleason score and initial prostate-specific antigen) remained predictive of various APFs. No significant predictors for PFS were found on MVA, although certain canonical predictors (eg, National Comprehensive Cancer Network risk group) were significant predictors of PFS on univariate analysis (UVA). PCA3 score was not a significant predictor of PFS on either UVA or MVA.ConclusionUnlike in lower risk cohorts, increasing PCA3 score was not associated with any APF in this higher risk cohort, despite enrichment for APFs, nor was it associated with PFS. Notably, multiple known preoperative predictors for APFs were significant on MVA, and multiple predictors were associated with PFS on UVA. Therefore, PCA3 may not be a useful adjunct predictive marker in men with intermediate- or high-risk PCa.
- Published
- 2017
70. The Role of PSMA PET/CT and PET/MRI in the Initial Staging of Prostate Cancer
- Author
-
Murthy, Vishnu, Sonni, Ida, Jariwala, Namasvi, Juarez, Roxanna, Reiter, Robert E., Raman, Steven S., and Hope, Thomas A.
- Published
- 2021
- Full Text
- View/download PDF
71. Multiregional Radiogenomic Assessment of Prostate Microenvironments with Multiparametric MR Imaging and DNA Whole-Exome Sequencing of Prostate Glands with Adenocarcinoma
- Author
-
Jamshidi, Neema, Margolis, Daniel J, Raman, Steven, Huang, Jiaoti, Reiter, Robert E, and Kuo, Michael D
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Prostate Cancer ,Aging ,Digestive Diseases ,Biomedical Imaging ,Human Genome ,Cancer ,Genetics ,Urologic Diseases ,Clinical Research ,Aetiology ,2.1 Biological and endogenous factors ,Adenocarcinoma ,Aged ,Biomarkers ,Tumor ,Early Detection of Cancer ,Exome ,Genetic Predisposition to Disease ,Genomics ,Humans ,Imaging ,Three-Dimensional ,Magnetic Resonance Imaging ,Male ,Neoplasm Grading ,Phylogeny ,Prostatic Neoplasms ,Retrospective Studies ,Tumor Microenvironment ,Medical and Health Sciences ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
Purpose To assess the underlying genomic variation of prostate gland microenvironments of patients with prostate adenocarcinoma in the context of colocalized multiparametric magnetic resonance (MR) imaging and histopathologic assessment of normal and abnormal regions by using whole-exome sequencing. Materials and Methods Six patients with prostate adenocarcinoma who underwent robotic prostatectomy with whole-mount preservation of the prostate were identified, which enabled spatial mapping between preoperative multiparametric MR imaging and the gland. Four regions of interest were identified within each gland, including regions found to be normal and abnormal via histopathologic analysis. Whole-exome DNA sequencing (>50 times coverage) was performed on each of these spatially targeted regions. Radiogenomic analysis of imaging and mutation data were performed with hierarchical clustering, phylogenetic analysis, and principal component analysis. Results Radiogenomic multiparametric MR imaging and whole-exome spatial characterization in six patients with prostate adenocarcinoma (three patients, Gleason score of 3 + 4; and three patients, Gleason score of 4 + 5) was performed across 23 spatially distinct regions. Hierarchical clustering separated histopathologic analysis-proven high-grade lesions from the normal regions, and this reflected concordance between multiparametric MR imaging and resultant histopathologic analysis in all patients. Seventy-seven mutations involving 29 cancer-associated genes across the 23 spatially distinct prostate samples were identified. There was no significant difference in mutation load in cancer-associated genes between regions that were proven to be normal via histopathologic analysis (34 mutations per sample ± 19), mildly suspicious via multiparametric MR imaging (37 mutations per sample ± 21), intermediately suspicious via multiparametric MR imaging (31 mutations per sample ± 15), and high-grade cancer (33 mutations per sample ± 18) (P = .30). Principal component analysis resolved samples from different patients and further classified samples (regardless of histopathologic status) from prostate glands with Gleason score 3 + 4 versus 4 + 5 samples. Conclusion Multiregion spatial multiparametric MR imaging and whole-exome radiogenomic analysis of prostate glands with adenocarcinoma shows a continuum of mutations across regions that were found via histologic analysis to be high grade and normal. © RSNA, 2017 Online supplemental material is available for this article.
- Published
- 2017
72. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.
- Author
-
Kishan, Amar U, Shaikh, Talha, Wang, Pin-Chieh, Reiter, Robert E, Said, Jonathan, Raghavan, Govind, Nickols, Nicholas G, Aronson, William J, Sadeghi, Ahmad, Kamrava, Mitchell, Demanes, David Jeffrey, Steinberg, Michael L, Horwitz, Eric M, Kupelian, Patrick A, and King, Christopher R
- Subjects
Humans ,Adenocarcinoma ,Prostatic Neoplasms ,Neoplasm Metastasis ,Androgen Antagonists ,Prognosis ,Treatment Failure ,Radiotherapy ,Brachytherapy ,Prostatectomy ,Multivariate Analysis ,Proportional Hazards Models ,Retrospective Studies ,Adult ,Aged ,Aged ,80 and over ,Middle Aged ,Male ,Kaplan-Meier Estimate ,Neoplasm Grading ,Gleason 10 ,Gleason 9 ,Radical prostatectomy ,Prostate Cancer ,Rare Diseases ,Patient Safety ,Urologic Diseases ,Clinical Research ,Cancer ,Evaluation of treatments and therapeutic interventions ,6.5 Radiotherapy and other non-invasive therapies ,Clinical Sciences ,Urology & Nephrology - Abstract
BackgroundThe long natural history of prostate cancer (CaP) limits comparisons of efficacy between radical prostatectomy (RP) and external beam radiotherapy (EBRT), since patients treated years ago received treatments considered suboptimal by modern standards (particularly with regards to androgen deprivation therapy [ADT] and radiotherapy dose-escalation]. Gleason score (GS) 9-10 CaP is particularly aggressive, and clinically-relevant endpoints occur early, facilitating meaningful comparisons.ObjectiveTo compare outcomes of patients with GS 9-10 CaP following EBRT, extremely-dose escalated radiotherapy (as exemplified by EBRT+brachytherapy [EBRT+BT]), and RP.Design, setting, participantsRetrospective analysis of 487 patients with biopsy GS 9-10 CaP treated between 2000 and 2013 (230 with EBRT, 87 with EBRT+BT, and 170 with RP). Most radiotherapy patients received ADT and dose-escalated radiotherapy.Outcome measurements and statistical analysisKaplan-Meier analysis and multivariate Cox regression estimated and compared 5-yr and 10-yr rates of distant metastasis-free survival, cancer-specific survival (CSS), and overall survival (OS).Results and limitationsThe median follow-up was 4.6 yr. Local salvage and systemic salvage were performed more frequently in RP patients (49.0% and 30.1%) when compared with either EBRT patients (0.9% and 19.7%) or EBRT+BT patients (1.2% and 16.1%, p
- Published
- 2017
73. Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology
- Author
-
Priester, Alan, Natarajan, Shyam, Khoshnoodi, Pooria, Margolis, Daniel J, Raman, Steven S, Reiter, Robert E, Huang, Jiaoti, Grundfest, Warren, and Marks, Leonard S
- Subjects
Biomedical Imaging ,Aging ,Cancer ,Prostate Cancer ,Prevention ,Clinical Research ,Urologic Diseases ,Aged ,Humans ,Imaging ,Three-Dimensional ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Models ,Anatomic ,Prostate ,Prostatectomy ,Prostatic Neoplasms ,Retrospective Studies ,prostatic neoplasms ,magnetic resonance imaging ,diagnostic errors ,pathology ,surgical ,image processing ,computer-assisted - Abstract
PurposeWe evaluated the accuracy of magnetic resonance imaging in determining the size and shape of localized prostate cancer.Materials and methodsThe subjects were 114 men who underwent multiparametric magnetic resonance imaging before radical prostatectomy with patient specific mold processing of the specimen from 2013 to 2015. T2-weighted images were used to contour the prostate capsule and cancer suspicious regions of interest. The contours were used to design and print 3-dimensional custom molds, which permitted alignment of excised prostates with magnetic resonance imaging scans. Tumors were reconstructed in 3 dimensions from digitized whole mount sections. Tumors were then matched with regions of interest and the relative geometries were compared.ResultsOf the 222 tumors evident on whole mount sections 118 had been identified on magnetic resonance imaging. For the 118 regions of interest mean volume was 0.8 cc and the longest 3-dimensional diameter was 17 mm. However, for matched pathological tumors, of which most were Gleason score 3 + 4 or greater, mean volume was 2.5 cc and the longest 3-dimensional diameter was 28 mm. The median tumor had a 13.5 mm maximal extent beyond the magnetic resonance imaging contour and 80% of cancer volume from matched tumors was outside region of interest boundaries. Size estimation was most accurate in the axial plane and least accurate along the base-apex axis.ConclusionsMagnetic resonance imaging consistently underestimates the size and extent of prostate tumors. Prostate cancer foci had an average diameter 11 mm longer and a volume 3 times greater than T2-weighted magnetic resonance imaging segmentations. These results may have important implications for the assessment and treatment of prostate cancer.
- Published
- 2017
74. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer
- Author
-
Stoyanova, Tanya, Riedinger, Mireille, Lin, Shu, Faltermeier, Claire M, Smith, Bryan A, Zhang, Kelvin X, Going, Catherine C, Goldstein, Andrew S, Lee, John K, Drake, Justin M, Rice, Meghan A, Hsu, En-Chi, Nowroozizadeh, Behdokht, Castor, Brandon, Orellana, Sandra Y, Blum, Steven M, Cheng, Donghui, Pienta, Kenneth J, Reiter, Robert E, Pitteri, Sharon J, Huang, Jiaoti, and Witte, Owen N
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Urologic Diseases ,Prostate Cancer ,Cancer ,Aging ,Amyloid Precursor Protein Secretases ,Animals ,Biomarkers ,Cell Line ,Tumor ,Cell Nucleus ,Disease Models ,Animal ,Disease Progression ,Epithelial-Mesenchymal Transition ,Gene Expression ,Gene Expression Profiling ,Heterografts ,Humans ,Immunohistochemistry ,Male ,Mice ,Mitogen-Activated Protein Kinases ,Neoplasm Grading ,Neoplasm Metastasis ,Phenotype ,Prostatic Neoplasms ,Castration-Resistant ,Proto-Oncogene Proteins c-akt ,Proto-Oncogene Proteins c-myc ,Receptor ,Notch1 ,Signal Transduction ,Tumor Burden ,raf Kinases ,ras Proteins ,prostate ,cancer ,Notch1 - Abstract
Metastatic castration-resistant prostate cancer (CRPC) is the primary cause of prostate cancer-specific mortality. Defining new mechanisms that can predict recurrence and drive lethal CRPC is critical. Here, we demonstrate that localized high-risk prostate cancer and metastatic CRPC, but not benign prostate tissues or low/intermediate-risk prostate cancer, express high levels of nuclear Notch homolog 1, translocation-associated (Notch1) receptor intracellular domain. Chronic activation of Notch1 synergizes with multiple oncogenic pathways altered in early disease to promote the development of prostate adenocarcinoma. These tumors display features of epithelial-to-mesenchymal transition, a cellular state associated with increased tumor aggressiveness. Consistent with its activation in clinical CRPC, tumors driven by Notch1 intracellular domain in combination with multiple pathways altered in prostate cancer are metastatic and resistant to androgen deprivation. Our study provides functional evidence that the Notch1 signaling axis synergizes with alternative pathways in promoting metastatic CRPC and may represent a new therapeutic target for advanced prostate cancer.
- Published
- 2016
75. Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer
- Author
-
Parikh, Neil R., Chang, Eric M., Nickols, Nicholas G., Rettig, Matthew B., Raldow, Ann C., Steinberg, Michael L., Koontz, Bridget F., Vapiwala, Neha, Deville, Curtiland, Feng, Felix Y., Spratt, Daniel E., Reiter, Robert E., Phillips, Ryan, Ost, Piet, Tran, Phuoc T., and Kishan, Amar U.
- Published
- 2020
- Full Text
- View/download PDF
76. Prostate cancer
- Author
-
Rebello, Richard J., Oing, Christoph, Knudsen, Karen E., Loeb, Stacy, Johnson, David C., Reiter, Robert E., Gillessen, Silke, Van der Kwast, Theodorus, and Bristow, Robert G.
- Published
- 2021
- Full Text
- View/download PDF
77. Prostate cancer detection with magnetic resonance‐ultrasound fusion biopsy: The role of systematic and targeted biopsies
- Author
-
Filson, Christopher P, Natarajan, Shyam, Margolis, Daniel JA, Huang, Jiaoti, Lieu, Patricia, Dorey, Frederick J, Reiter, Robert E, and Marks, Leonard S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Prevention ,Prostate Cancer ,Clinical Research ,Urologic Diseases ,Biomedical Imaging ,Cancer ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Aged ,Biomarkers ,Tumor ,Biopsy ,Needle ,Humans ,Image-Guided Biopsy ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Multimodal Imaging ,Odds Ratio ,Predictive Value of Tests ,Prospective Studies ,Prostate-Specific Antigen ,Prostatic Neoplasms ,Ultrasonography ,Interventional ,biopsy ,cancer staging ,diagnostic imaging ,magnetic resonance imaging ,prostate cancer ,Public Health and Health Services ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Public health - Abstract
BackgroundThe current study was conducted to evaluate the performance of magnetic resonance (MR)-ultrasound-guided fusion biopsy in diagnosing clinically significant prostate cancer (csCaP).MethodsA total of 1042 men underwent multiparametric MR imaging (mpMRI) and fusion biopsy consecutively in a prospective trial (2009-2014). An expert reader graded mpMRI regions of interest (ROIs) as 1 to 5 using published protocols. The fusion biopsy device was used to obtain targeted cores from ROIs (when present) followed by a fusion image-guided, 12-core systematic biopsy in all men, even if no suspicious ROI was noted. The primary endpoint of the study was the detection of csCaP (ie, Gleason score ≥ 7).ResultsAmong 825 men with ≥ 1 suspicious ROI of ≥ grade 3, 289 (35%) were found to have csCaP. Powerful predictors of csCaP were ROI grade (grade 5 vs grade 3: odds ratio, 6.5 [P
- Published
- 2016
78. Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADAR
- Author
-
Ong, Wee Loon, primary, Nikitas, John, additional, Joseph, David, additional, Steigler, Allison, additional, Millar, Jeremy, additional, Valle, Luca, additional, Steinberg, Michael L., additional, Ma, Ting Martin, additional, Reiter, Robert E., additional, Rettig, Matthew B., additional, Nickols, Nicholas G., additional, Chang, Albert, additional, Zaorsky, Nicholas G., additional, Spratt, Daniel E., additional, Romero, Tahmineh, additional, and Kishan, Amar U., additional
- Published
- 2023
- Full Text
- View/download PDF
79. Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer
- Author
-
Tsai, Wen-Ting K, Zettlitz, Kirstin A, Dahlbom, Magnus, Reiter, Robert E, and Wu, Anna M
- Published
- 2020
- Full Text
- View/download PDF
80. Accelerated echo planar J‐resolved spectroscopic imaging in prostate cancer: a pilot validation of non‐linear reconstruction using total variation and maximum entropy
- Author
-
Nagarajan, Rajakumar, Iqbal, Zohaib, Burns, Brian, Wilson, Neil E, Sarma, Manoj K, Margolis, Daniel A, Reiter, Robert E, Raman, Steven S, and Thomas, M Albert
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Biomedical Imaging ,Cancer ,Urologic Diseases ,Prostate Cancer ,Aged ,Biomarkers ,Tumor ,Echo-Planar Imaging ,Entropy ,Humans ,Image Enhancement ,Image Interpretation ,Computer-Assisted ,Male ,Middle Aged ,Nonlinear Dynamics ,Pilot Projects ,Prostatic Neoplasms ,Reproducibility of Results ,Sensitivity and Specificity ,MRS ,prostate cancer ,4D EP-JRESI ,citrate ,myo-inositol ,Glx ,echo planar spectroscopic imaging ,Medicinal and Biomolecular Chemistry ,Biomedical Engineering ,Nuclear Medicine & Medical Imaging ,Clinical sciences ,Biomedical engineering - Abstract
The overlap of metabolites is a major limitation in one-dimensional (1D) spectral-based single-voxel MRS and multivoxel-based MRSI. By combining echo planar spectroscopic imaging (EPSI) with a two-dimensional (2D) J-resolved spectroscopic (JPRESS) sequence, 2D spectra can be recorded in multiple locations in a single slice of prostate using four-dimensional (4D) echo planar J-resolved spectroscopic imaging (EP-JRESI). The goal of the present work was to validate two different non-linear reconstruction methods independently using compressed sensing-based 4D EP-JRESI in prostate cancer (PCa): maximum entropy (MaxEnt) and total variation (TV). Twenty-two patients with PCa with a mean age of 63.8 years (range, 46-79 years) were investigated in this study. A 4D non-uniformly undersampled (NUS) EP-JRESI sequence was implemented on a Siemens 3-T MRI scanner. The NUS data were reconstructed using two non-linear reconstruction methods, namely MaxEnt and TV. Using both TV and MaxEnt reconstruction methods, the following observations were made in cancerous compared with non-cancerous locations: (i) higher mean (choline + creatine)/citrate metabolite ratios; (ii) increased levels of (choline + creatine)/spermine and (choline + creatine)/myo-inositol; and (iii) decreased levels of (choline + creatine)/(glutamine + glutamate). We have shown that it is possible to accelerate the 4D EP-JRESI sequence by four times and that the data can be reliably reconstructed using the TV and MaxEnt methods. The total acquisition duration was less than 13 min and we were able to detect and quantify several metabolites.
- Published
- 2015
81. Prostate diffusion imaging with distortion correction
- Author
-
Rakow-Penner, Rebecca A, White, Nathan S, Margolis, Daniel JA, Parsons, John Kellogg, Schenker-Ahmed, Natalie, Kuperman, Joshua M, Bartsch, Hauke, Choi, Hyung W, Bradley, William G, Shabaik, Ahmed, Huang, Jiaoti, Liss, Michael A, Marks, Leonard, Kane, Christopher J, Reiter, Robert E, Raman, Steven S, Karow, David S, and Dale, Anders M
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Prostate Cancer ,Urologic Diseases ,Cancer ,Biomedical Imaging ,Aging ,Contrast Media ,Diffusion Magnetic Resonance Imaging ,Gadolinium ,Humans ,Image Enhancement ,Magnetic Resonance Imaging ,Male ,Prostate ,Prostatic Neoplasms ,Prostate cancer ,MRI ,Diffusion-weighted imaging ,Distortion correction ,Biomedical Engineering ,Cognitive Sciences ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
PurposeDiffusion imaging in the prostate is susceptible to distortion from B0 inhomogeneity. Distortion correction in prostate imaging is not routinely performed, resulting in diffusion images without accurate localization of tumors. We performed and evaluated distortion correction for diffusion imaging in the prostate.Materials and methods28 patients underwent pre-operative MRI (T2, Gadolinium perfusion, diffusion at b=800 s/mm(2)). The restriction spectrum protocol parameters included b-values of 0, 800, 1500, and 4000 s/mm(2) in 30 directions for each nonzero b-value. To correct for distortion, forward and reverse trajectories were collected at b=0 s/mm(2). Distortion maps were generated to reflect the offset of the collected data versus the corrected data. Whole-mount histology was available for correlation.ResultsAcross the 27 patients evaluated (excluding one patient due to data collection error), the average root mean square distortion distance of the prostate was 3.1 mm (standard deviation, 2.2mm; and maximum distortion, 12 mm).ConclusionImproved localization of prostate cancer by MRI will allow better surgical planning, targeted biopsies and image-guided treatment therapies. Distortion distances of up to 12 mm due to standard diffusion imaging may grossly misdirect treatment decisions. Distortion correction for diffusion imaging in the prostate improves tumor localization.
- Published
- 2015
82. A fully human scFv phage display library for rapid antibody fragment reformatting
- Author
-
Li, Keyu, Zettlitz, Kirstin A, Lipianskaya, Julia, Zhou, Yu, Marks, James D, Mallick, Parag, Reiter, Robert E, and Wu, Anna M
- Subjects
Biochemistry and Cell Biology ,Biological Sciences ,Biotechnology ,Amino Acid Sequence ,Base Sequence ,Humans ,Molecular Sequence Data ,Peptide Fragments ,Peptide Library ,Protein Engineering ,Single-Chain Antibodies ,Antibody fragment ,diabody ,N-cadherin ,phage display ,scFv ,Chemical Sciences ,Technology ,Biophysics ,Biochemistry and cell biology ,Industrial biotechnology - Abstract
Phage display libraries of human single-chain variable fragments (scFvs) are a reliable source of fully human antibodies for scientific and clinical applications. Frequently, scFvs form the basis of larger, bivalent formats to increase valency and avidity. A small and versatile bivalent antibody fragment is the diabody, a cross-paired scFv dimer (∼55 kDa). However, generation of diabodies from selected scFvs requires decreasing the length of the interdomain scFv linker, typically by overlap PCR. To simplify this process, we designed two scFv linkers with integrated restriction sites for easy linker length reduction (17-residue to 7-residue or 18-residue to 5-residue, respectively) and generated two fully human scFv phage display libraries. The larger library (9 × 10(9) functional members) was employed for selection against a model antigen, human N-cadherin, yielding novel scFv clones with low nanomolar monovalent affinities. ScFv clones from both libraries were reformatted into diabodies by restriction enzyme digestion and re-ligation. Size-exclusion chromatography analysis confirmed the proper dimerization of most of the diabodies. In conclusion, these specially designed scFv phage display libraries allow us to rapidly reformat the selected scFvs into diabodies, which can greatly accelerate early stage antibody development when bivalent fragments are needed for candidate screening.
- Published
- 2015
83. Efficacy of a preprostatectomy multi-modal penile rehabilitation regimen on recovery of postoperative erectile function
- Author
-
Osadchiy, Vadim, Eleswarapu, Sriram V., Mills, Steven A., Pollard, Matthew E., Reiter, Robert E., and Mills, Jesse N.
- Published
- 2020
- Full Text
- View/download PDF
84. [89Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model
- Author
-
Zettlitz, Kirstin A., Tsai, Wen-Ting K., Knowles, Scott M., Salazar, Felix B., Kobayashi, Naoko, Reiter, Robert E., and Wu, Anna M.
- Published
- 2020
- Full Text
- View/download PDF
85. Characteristics of Detected and Missed Prostate Cancer Foci on 3-T Multiparametric MRI Using an Endorectal Coil Correlated With Whole-Mount Thin-Section Histopathology.
- Author
-
Tan, Nelly, Margolis, Daniel J, Lu, David Y, King, Kevin G, Huang, Jiaoti, Reiter, Robert E, and Raman, Steven S
- Subjects
Urologic Diseases ,Cancer ,Clinical Research ,Aging ,Prostate Cancer ,Prevention ,Biomedical Imaging ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Adenocarcinoma ,Biopsy ,Diagnostic Errors ,Humans ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Neoplasm Grading ,Prostatectomy ,Prostatic Neoplasms ,Sensitivity and Specificity ,multiparametric prostate MRI ,prostate cancer ,Clinical Sciences ,Nuclear Medicine & Medical Imaging - Abstract
ObjectiveThe objective of this study was to determine the characteristics of prostate cancer foci missed on 3-T multiparametric MRI performed with an endorectal coil.Materials and methodsThe MRI examinations of 122 patients who underwent 3-T multiparametric MRI of the prostate with an endorectal coil were compared with whole-mount histopathology obtained after radical prostatectomy. The mean age of the patients was 60.6 years (SD, 7.6 years), and the mean prostate-specific antigen value was 7.2 ng/mL (SD, 5.9 ng/mL). The clinical, multiparametric MRI (i.e., T2-weighted imaging, diffusion-weighted imaging, and dynamic contrast-enhanced imaging), and histopathologic features were obtained. After an independent review, two blinded genitourinary radiologists matched each case with a genitourinary pathologist. A structured reporting system was used to classify the multiparametric MRI features of each MRI-detected lesion. A chi-square analysis was performed for categoric variables, and the t test was performed for continuous variables.ResultsOn whole-mount histopathology, 285 prostate cancer foci were detected in 122 patients. Of the 285 cancer foci detected at histopathology, 153 (53.3%) were missed on MRI and 132 (46.7%) were detected on MRI. Of the missed lesions, 75.2% were low-grade prostate cancer. Multiparametric MRI had a significantly higher sensitivity for prostate cancer foci 1 cm or larger than for subcentimeter foci (81.1% vs 18.9%, respectively; p < 0.001), for lesions with a Gleason score of 7 or greater than for lesions with a Gleason score of 6 (72.7% vs 27.3%; p < 0.01), and for index lesions than for satellite lesions (80.3% vs 20.8%; p < 0.01). The 3-T multiparametric MRI examinations showed a higher detection rate for lesions in the midgland or base of the gland compared with lesions in the apex (52.3% vs 22.0%, respectively; p < 0.01).ConclusionCompared with the prostate cancer lesions that were detected on multiparametric MRI, the prostate cancer lesions that were missed were significantly smaller, were more likely to be low-grade lesions (i.e., Gleason score of 6), were more commonly satellite lesions, and were more likely to be located in the prostatic apex.
- Published
- 2015
86. Ultrasensitive Prostate Specific Antigen after Prostatectomy Reliably Identifies Patients Requiring Postoperative Radiotherapy
- Author
-
Kang, Jung Julie, Reiter, Robert E, Steinberg, Michael L, and King, Christopher R
- Subjects
Prevention ,Clinical Research ,Prostate Cancer ,Patient Safety ,Aging ,Cancer ,Urologic Diseases ,Humans ,Male ,Neoplasm Recurrence ,Local ,Patient Selection ,Postoperative Care ,Prostate-Specific Antigen ,Prostatectomy ,Prostatic Neoplasms ,Reproducibility of Results ,Retrospective Studies ,Sensitivity and Specificity ,prostatic neoplasms ,prostatectomy ,prostate-specific antigen ,neoplasm recurrence ,local ,diagnosis - Abstract
PurposeIntegrating ultrasensitive prostate specific antigen with surveillance in patients at high risk after radical prostatectomy potentially optimizes treatment by correctly identifying recurrence, promoting an early salvage strategy and minimizing overtreatment. We tested the power of postoperative ultrasensitive prostate specific antigen to identify eventual biochemical failure.Materials and methodsWe identified 247 patients at high risk with a median followup of 44 months who underwent radical prostatectomy from 1991 to 2013. Each patient had extraprostatic extension and/or a positive margin. Surgical technique, initial prostate specific antigen, pathology findings and postoperative prostate specific antigen were analyzed. The ultrasensitive prostate specific antigen assay threshold was 0.01 ng/ml. Conventional biochemical relapse was defined as prostate specific antigen 0.2 ng/ml or greater. Kaplan-Meier and Cox multivariate analyses were done to compare the rates of ultrasensitive prostate specific antigen recurrence and conventional biochemical relapse.ResultsSensitivity analysis revealed that ultrasensitive prostate specific antigen 0.03 ng/ml or greater was the optimal threshold to identify recurrence. A first postoperative ultrasensitive value of 0.03 ng/ml or greater, Gleason grade, T stage, initial prostate specific antigen and margin status predicted conventional biochemical relapse. On multivariate analysis only a first postoperative ultrasensitive value of 0.03 ng/ml or greater, Gleason grade and T stage independently predicted conventional biochemical relapse. First postoperative ultrasensitive prostate specific antigen 0.03 ng/ml or greater conferred the highest risk (HR 8.5, p < 0.0001) and identified conventional biochemical relapse with greater sensitivity than undetectable first conventional prostate specific antigen (70% vs 46%). Any postoperative prostate specific antigen 0.03 ng/ml or greater captured all failures missed by the first postoperative value (100% sensitivity) with accuracy (96% specificity). Defining failure at an ultrasensitive value of 0.03 ng/ml or greater yielded a median lead time advantage of 18 months (mean 24) over the conventional definition of prostate specific antigen 0.2 ng/ml or greater.ConclusionsUltrasensitive prostate specific antigen 0.03 ng/ml or greater is an independent factor that identifies biochemical relapse more accurately than any traditional risk factors and confers a significant lead time advantage. This factor enables critical decisions on the timing of and indication for postoperative radiotherapy in patients at high risk after radical prostatectomy.
- Published
- 2015
87. MRI-Derived Restriction Spectrum Imaging Cellularity Index is Associated with High Grade Prostate Cancer on Radical Prostatectomy Specimens
- Author
-
Liss, Michael A, White, Nathan S, Parsons, J Kellogg, Schenker-Ahmed, Natalie M, Rakow-Penner, Rebecca, Kuperman, Joshua M, Bartsch, Hauke, Choi, Hyung W, Mattrey, Robert F, Bradley, William G, Shabaik, Ahmed, Huang, Jiaoti, Margolis, Daniel JA, Raman, Steven S, Marks, Leonard S, Kane, Christopher J, Reiter, Robert E, Dale, Anders M, and Karow, David S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Biomedical Imaging ,Cancer ,Aging ,Urologic Diseases ,Prostate Cancer ,prostate ,MRI imaging ,prostate cancer ,cellula My ,Gleason score ,cellularity ,Clinical sciences ,Oncology and carcinogenesis - Abstract
PurposeWe evaluate a novel magnetic resonance imaging (MRI) technique to improve detection of aggressive prostate cancer (PCa).Materials and methodsWe performed a retrospective analysis of pre-surgical prostate MRI scans using an advanced diffusion-weighted imaging technique called restriction spectrum imaging (RSI), which can be presented as a normalized z-score statistic. Scans were acquired prior to radical prostatectomy. Prostatectomy specimens were processed using whole-mount sectioning and regions of interest (ROIs) were drawn around individual PCa tumors. Corresponding ROIs were drawn on the MRI imaging and paired with ROIs in regions with no pathology. RSI z-score and conventional apparent diffusion coefficient (ADC) values were recorded for each ROI. Paired t-test, ANOVA, and logistic regression analyses were performed.ResultsWe evaluated 28 patients with 64 ROIs (28 benign and 36 PCa). The mean difference in RSI z-score (PCa ROI-Benign ROI) was 2.17 (SE = 0.11; p
- Published
- 2015
88. Applications of ImmunoPET: Using 124I-Anti-PSCA A11 Minibody for Imaging Disease Progression and Response to Therapy in Mouse Xenograft Models of Prostate Cancer
- Author
-
Knowles, Scott M, Tavaré, Richard, Zettlitz, Kirstin A, Rochefort, Matthew M, Salazar, Felix B, Jiang, Ziyue Karen, Reiter, Robert E, and Wu, Anna M
- Subjects
Urologic Diseases ,Biomedical Imaging ,Cancer ,Prostate Cancer ,Biotechnology ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Androgen Antagonists ,Animals ,Antigens ,Neoplasm ,Antineoplastic Agents ,Benzamides ,Disease Models ,Animal ,Disease Progression ,GPI-Linked Proteins ,Heterografts ,Humans ,Immunoglobulin Fragments ,Iodine Radioisotopes ,Male ,Mice ,Neoplasm Proteins ,Nitriles ,Phenylthiohydantoin ,Positron-Emission Tomography ,Prostatic Neoplasms ,Tissue Distribution ,Treatment Outcome ,Tumor Burden ,X-Ray Microtomography ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeProstate stem cell antigen (PSCA) is highly expressed in local prostate cancers and prostate cancer bone metastases and its expression correlates with androgen receptor activation and a poor prognosis. In this study, we investigate the potential clinical applications of immunoPET with the anti-PSCA A11 minibody, an antibody fragment optimized for use as an imaging agent. We compare A11 minibody immunoPET to (18)F-Fluoride PET bone scans for detecting prostate cancer bone tumors and evaluate the ability of the A11 minibody to image tumor response to androgen deprivation.Experimental designOsteoblastic, PSCA-expressing, LAPC-9 intratibial xenografts were imaged with serial (124)I-anti-PSCA A11 minibody immunoPET and (18)F-Fluoride bone scans. Mice bearing LAPC-9 subcutaneous xenografts were treated with either vehicle or MDV-3100 and imaged with A11 minibody immunoPET/CT scans pre- and posttreatment. Ex vivo flow cytometry measured the change in PSCA expression in response to androgen deprivation.ResultsA11 minibody demonstrated improved sensitivity and specificity over (18)F-Fluoride bone scans for detecting LAPC-9 intratibial xenografts at all time points. LAPC-9 subcutaneous xenografts showed downregulation of PSCA when treated with MDV-3100 which A11 minibody immunoPET was able to detect in vivo.ConclusionsA11 minibody immunoPET has the potential to improve the sensitivity and specificity of clinical prostate cancer metastasis detection over bone scans, which are the current clinical standard-of-care. A11 minibody immunoPET additionally has the potential to image the activity of the androgen signaling axis in vivo which may help evaluate the clinical response to androgen deprivation and the development of castration resistance.
- Published
- 2014
89. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy for Prediction of Final Prostate Pathology
- Author
-
Le, Jesse D, Stephenson, Samuel, Brugger, Michelle, Lu, David Y, Lieu, Patricia, Sonn, Geoffrey A, Natarajan, Shyam, Dorey, Frederick J, Huang, Jiaoti, Margolis, Daniel JA, Reiter, Robert E, and Marks, Leonard S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Biomedical Imaging ,Aging ,Urologic Diseases ,Prostate Cancer ,Clinical Research ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Aged ,Biopsy ,Needle ,Endosonography ,Follow-Up Studies ,Humans ,Image-Guided Biopsy ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Neoplasm Grading ,Neoplasm Staging ,Prospective Studies ,Prostatectomy ,Prostatic Neoplasms ,Rectum ,Reproducibility of Results ,prostatic neoplasms ,magnetic resonance imaging ,ultrasonography ,biopsy ,prostatectomy - Abstract
PurposeWe explored the impact of magnetic resonance imaging-ultrasound fusion prostate biopsy on the prediction of final surgical pathology.Materials and methodsA total of 54 consecutive men undergoing radical prostatectomy at UCLA after fusion biopsy were included in this prospective, institutional review board approved pilot study. Using magnetic resonance imaging-ultrasound fusion, tissue was obtained from a 12-point systematic grid (mapping biopsy) and from regions of interest detected by multiparametric magnetic resonance imaging (targeted biopsy). A single radiologist read all magnetic resonance imaging, and a single pathologist independently rereviewed all biopsy and whole mount pathology, blinded to prior interpretation and matched specimen. Gleason score concordance between biopsy and prostatectomy was the primary end point.ResultsMean patient age was 62 years and median prostate specific antigen was 6.2 ng/ml. Final Gleason score at prostatectomy was 6 (13%), 7 (70%) and 8-9 (17%). A tertiary pattern was detected in 17 (31%) men. Of 45 high suspicion (image grade 4-5) magnetic resonance imaging targets 32 (71%) contained prostate cancer. The per core cancer detection rate was 20% by systematic mapping biopsy and 42% by targeted biopsy. The highest Gleason pattern at prostatectomy was detected by systematic mapping biopsy in 54%, targeted biopsy in 54% and a combination in 81% of cases. Overall 17% of cases were upgraded from fusion biopsy to final pathology and 1 (2%) was downgraded. The combination of targeted biopsy and systematic mapping biopsy was needed to obtain the best predictive accuracy.ConclusionsIn this pilot study magnetic resonance imaging-ultrasound fusion biopsy allowed for the prediction of final prostate pathology with greater accuracy than that reported previously using conventional methods (81% vs 40% to 65%). If confirmed, these results will have important clinical implications.
- Published
- 2014
90. Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer
- Author
-
Sonn, Geoffrey A, Filson, Christopher P, Chang, Edward, Natarajan, Shyam, Margolis, Daniel J, Macairan, Malu, Lieu, Patricia, Huang, Jiaoti, Dorey, Frederick J, Reiter, Robert E, and Marks, Leonard S
- Subjects
Clinical Research ,Cancer ,Biomedical Imaging ,Urologic Diseases ,Prostate Cancer ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Biopsy ,Humans ,Imaging ,Three-Dimensional ,Magnetic Resonance Imaging ,Male ,Prostatic Neoplasms ,Surgery ,Computer-Assisted ,Ultrasonography ,Interventional ,Watchful Waiting ,Prostatic neoplasms ,Magnetic resonance imaging ,Ultrasonography ,Active surveillance ,Oncology and Carcinogenesis ,Urology & Nephrology - Abstract
ObjectivesTargeted biopsy, using magnetic resonance (MR)-ultrasound (US) fusion, may allow tracking of specific cancer sites in the prostate. We aimed to evaluate the initial use of the technique to follow tumor sites in men on active surveillance of prostate cancer.Methods and materialsA total of 53 men with prostate cancer (all T1c category) underwent rebiopsy of 74 positive biopsy sites, which were tracked and targeted using the Artemis MR-US fusion device (Eigen, Grass Valley, CA) from March 2010 through January 2013. The initial biopsy included 12 cores from a standard template (mapped by software) and directed biopsies from regions of interest seen on MR imaging (MRI). In the repeat biopsy, samples were taken from sites containing cancer at the initial biopsy. Outcomes of interest at second MR-US biopsy included (a) presence of any cancer and (b) presence of clinically significant cancer.ResultsAll cancers on initial biopsy had either Gleason score 3+3 = 6 (n = 63) or 3+4 = 7 (n = 11). At initial biopsy, 23 cancers were within an MRI target, and 51 were found on systematic biopsy. Cancer detection rate on repeat biopsy (29/74, 39%) was independent of Gleason score on initial biopsy (P = not significant) but directly related to initial cancer core length (P
- Published
- 2014
91. Diffusion-Weighted Imaging in Cancer: Physical Foundations and Applications of Restriction Spectrum Imaging
- Author
-
White, Nathan S, McDonald, Carrie R, Farid, Niky, Kuperman, Josh, Karow, David, Schenker-Ahmed, Natalie M, Bartsch, Hauke, Rakow-Penner, Rebecca, Holland, Dominic, Shabaik, Ahmed, Bjørnerud, Atle, Hope, Tuva, Hattangadi-Gluth, Jona, Liss, Michael, Parsons, J Kellogg, Chen, Clark C, Raman, Steve, Margolis, Daniel, Reiter, Robert E, Marks, Leonard, Kesari, Santosh, Mundt, Arno J, Kane, Christopher J, Carter, Bob S, Bradley, William G, and Dale, Anders M
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Bioengineering ,Biomedical Imaging ,Cancer ,Breast Cancer ,Diagnostic Imaging ,Diffusion Magnetic Resonance Imaging ,Humans ,Medical Oncology ,Neoplasms ,Oncology & Carcinogenesis ,Biochemistry and cell biology ,Oncology and carcinogenesis - Abstract
Diffusion-weighted imaging (DWI) has been at the forefront of cancer imaging since the early 2000s. Before its application in clinical oncology, this powerful technique had already achieved widespread recognition due to its utility in the diagnosis of cerebral infarction. Following this initial success, the ability of DWI to detect inherent tissue contrast began to be exploited in the field of oncology. Although the initial oncologic applications for tumor detection and characterization, assessing treatment response, and predicting survival were primarily in the field of neurooncology, the scope of DWI has since broadened to include oncologic imaging of the prostate gland, breast, and liver. Despite its growing success and application, misconceptions about the underlying physical basis of the DWI signal exist among researchers and clinicians alike. In this review, we provide a detailed explanation of the biophysical basis of diffusion contrast, emphasizing the difference between hindered and restricted diffusion, and elucidating how diffusion parameters in tissue are derived from the measurements via the diffusion model. We describe one advanced DWI modeling technique, called restriction spectrum imaging (RSI). This technique offers a more direct in vivo measure of tumor cells, due to its ability to distinguish separable pools of water within tissue based on their intrinsic diffusion characteristics. Using RSI as an example, we then highlight the ability of advanced DWI techniques to address key clinical challenges in neurooncology, including improved tumor conspicuity, distinguishing actual response to therapy from pseudoresponse, and delineation of white matter tracts in regions of peritumoral edema. We also discuss how RSI, combined with new methods for correction of spatial distortions inherent in diffusion MRI scans, may enable more precise spatial targeting of lesions, with implications for radiation oncology and surgical planning. See all articles in this Cancer Research section, "Physics in Cancer Research."
- Published
- 2014
92. Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging
- Author
-
Johnson, David C., Raman, Steven S., Mirak, Sohrab A., Kwan, Lorna, Bajgiran, Amirhossein M., Hsu, William, Maehara, Cleo K., Ahuja, Preeti, Faiena, Izak, Pooli, Aydin, Salmasi, Amirali, Sisk, Anthony, Felker, Ely R., Lu, David S.K., and Reiter, Robert E.
- Published
- 2019
- Full Text
- View/download PDF
93. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology
- Author
-
Kang, Jung Julie, Reiter, Robert E., Steinberg, Michael L., and King, Christopher R.
- Published
- 2018
- Full Text
- View/download PDF
94. The Role of Magnetic Resonance Imaging in Delineating Clinically Significant Prostate Cancer
- Author
-
Chamie, Karim, Sonn, Geoffrey A, Finley, David S, Tan, Nelly, Margolis, Daniel JA, Raman, Steven S, Natarajan, Shyam, Huang, Jiaoti, and Reiter, Robert E
- Subjects
Cancer ,Biomedical Imaging ,Urologic Diseases ,Prostate Cancer ,Clinical Research ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Aged ,Humans ,Magnetic Resonance Imaging ,Male ,Middle Aged ,Neoplasm Grading ,Preoperative Care ,Prostatectomy ,Prostatic Neoplasms ,Retrospective Studies ,Risk Assessment ,Clinical Sciences ,Urology & Nephrology - Abstract
ObjectiveTo determine whether multiparametric magnetic resonance imaging might improve the identification of patients with higher risk disease at diagnosis and thereby reduce the incidence of undergrading or understaging.MethodsWe retrospectively reviewed the clinical records of 115 patients who underwent multiparametric magnetic resonance imaging before radical prostatectomy. We used Epstein's criteria of insignificant disease with and without a magnetic resonance imaging (MRI) parameter (apparent diffusion coefficient) to calculate sensitivity, specificity, as well as negative and positive predictive values [NPV and PPV] across varying definitions of clinically significant cancer based on Gleason grade and tumor volume (0.2 mL, 0.5 mL, and 1.3 mL) on whole-mount prostate specimens. Logistic regression analysis was performed to determine the incremental benefit of MRI in delineating significant cancer.ResultsThe majority had a prostate-specific antigen from 4.1-10.0 (67%), normal rectal examinations (90%), biopsy Gleason score ≤ 6 (68%), and ≤ 2 cores positive (55%). Of the 58 patients pathologically staged with Gleason 7 or pT3 disease at prostatectomy, Epstein's criteria alone missed 12 patients (sensitivity of 79% and NPV of 68%). Addition of apparent diffusion coefficient improved the sensitivity and NPV for predicting significant disease at prostatectomy to 93% and 84%, respectively. MRI improved detection of large Gleason 6 (≥ 1.3 mL, P = .006) or Gleason ≥ 7 lesions of any size (P
- Published
- 2014
95. Multidimensional MR spectroscopic imaging of prostate cancer in vivo
- Author
-
Thomas, M Albert, Nagarajan, Rajakumar, Huda, Amir, Margolis, Daniel, Sarma, Manoj K, Sheng, Ke, Reiter, Robert E, and Raman, Steven S
- Subjects
Clinical Research ,Aging ,Urologic Diseases ,Cancer ,Prostate Cancer ,Biomedical Imaging ,Diagnostic Imaging ,Echo-Planar Imaging ,Humans ,Magnetic Resonance Spectroscopy ,Male ,Metabolome ,Prostate ,Prostatic Neoplasms ,prostate cancer ,magnetic resonance spectroscopy ,2D JPRESS ,2D L-COSY ,citrate ,spermine ,echo-planar spectroscopic imaging ,Medicinal and Biomolecular Chemistry ,Biomedical Engineering ,Clinical Sciences ,Nuclear Medicine & Medical Imaging - Abstract
Prostate cancer (PCa) is the second most common type of cancer among men in the United States. A major limitation in the management of PCa is an inability to distinguish, early on, cancers that will progress and become life threatening. One-dimensional (1D) proton ((1)H) MRS of the prostate provides metabolic information such as levels of choline (Ch), creatine (Cr), citrate (Cit), and spermine (Spm) that can be used to detect and diagnose PCa. Ex vivo high-resolution magic angle spinning (HR-MAS) of PCa specimens has revealed detection of more metabolites such as myo-inositol (mI), glutamate (Glu), and glutamine (Gln). Due to the J-modulation and signal overlap, it is difficult to quantitate Spm and other resonances in the prostate clearly by single- and multivoxel-based 1D MR spectroscopy. This limitation can be minimized by adding at least one more spectral dimension by which resonances can be spread apart, thereby increasing the spectral dispersion. However, recording of multivoxel-based two-dimensional (2D) MRS such as J-resolved spectroscopy (JPRESS) and correlated spectroscopy (L-COSY) combined with 2D or three-dimensional (3D) magnetic resonance spectroscopic imaging (MRSI) using conventional phase-encoding can be prohibitively long to be included in a clinical protocol. To reduce the long acquisition time required for spatial encoding, the echo-planar spectroscopic imaging (EPSI) technique has been combined with correlated spectroscopy to give four-dimensional (4D) echo-planar correlated spectroscopic imaging (EP-COSI) as well as J-resolved spectroscopic imaging (EP-JRESI) and the multi-echo (ME) variants. Further acceleration can be achieved using non-uniform undersampling (NUS) and reconstruction using compressed sensing (CS). Earlier versions of 2D MRS, theory of 2D MRS, spectral apodization filters, newer developments and the potential role of multidimensional MRS in PCa detection and management will be reviewed here.
- Published
- 2014
96. A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy
- Author
-
Salmasi, Amirali, Said, Jonathan, Shindel, Alan W., Khoshnoodi, Pooria, Felker, Ely R., Sisk, Anthony E., Jr., Grogan, Tristan, McCullough, Debbie, Bennett, John, Bailey, Helen, Lawrence, H. Jeffrey, Elashoff, David A., Marks, Leonard S., Raman, Steven S., Febbo, Phillip G., and Reiter, Robert E.
- Published
- 2018
- Full Text
- View/download PDF
97. Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials
- Author
-
Smith, Clayton P., primary, Xiang, Michael, additional, Armstrong, Wesley R., additional, Nickols, Nicholas G., additional, Steinberg, Michael L., additional, Reiter, Robert E., additional, Rettig, Matthew, additional, Weiner, Adam B., additional, Shen, John, additional, Valle, Luca, additional, Czernin, Johannes, additional, Calais, Jeremie, additional, and Kishan, Amar U., additional
- Published
- 2023
- Full Text
- View/download PDF
98. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study
- Author
-
Sandler, Kiri A., Cook, Ryan R., Ciezki, Jay P., Ross, Ashley E., Pomerantz, Mark M., Nguyen, Paul L., Shaikh, Talha, Tran, Phuoc T., Stock, Richard G., Merrick, Gregory S., Demanes, D. Jeffrey, Spratt, Daniel E., Abu-Isa, Eyad I., Wedde, Trude B., Lilleby, Wolfgang, Krauss, Daniel J., Shaw, Grace K., Alam, Ridwan, Reddy, Chandana A., Song, Daniel Y., Klein, Eric A., Stephenson, Andrew J., Tosoian, Jeffrey J., Hegde, John V., Yoo, Sun Mi, Fiano, Ryan, D'Amico, Anthony V., Nickols, Nicholas G., Aronson, William J., Sadeghi, Ahmad, Greco, Stephen C., Deville, Curtiland, McNutt, Todd, DeWeese, Theodore L., Reiter, Robert E., Said, Jonathan W., Steinberg, Michael L., Horwitz, Eric M., Kupelian, Patrick A., King, Christopher R., and Kishan, Amar U.
- Published
- 2018
- Full Text
- View/download PDF
99. 3T Multiparametric MRI: Comparison of Performance With and Without Endorectal Coil for Prostate Cancer Detection, PI-RADSv2 Category and Staging with Whole Mount Histopathology Correlation in 429 Patients
- Author
-
Afshari Mirak, Sohrab, Shakeri, Sepideh, Mohammadian Bajgiran, Amirhossein, Felker, Ely R., Sung, Kyung Hyun, Asvadi, Nazanin Hajarol, Khoshnoodi, Pooria, Markovic, Daniela, Ponzini, Danielle, Ahuja, Preeti, Sisk, Anthony, Reiter, Robert E., Lu, David, and Raman, Steven S.
- Published
- 2018
- Full Text
- View/download PDF
100. PI-RADSv2 Category on 3 Tesla Multiparametric Prostate MRI Predicts Oncologic Outcomes in Gleason 3+4 Prostate Cancer on Biopsy
- Author
-
Faiena, Izak, Salmasi, Amirali, Mendhiratta, Neil, Markovic, Daniela, Ahuja, Preeti, Hsu, William, Elashoff, David A., Raman, Steven S., and Reiter, Robert E.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.